Daratumumab induces cell-mediated cytotoxicity of primary effusion lymphoma and is active against refractory disease

Primary effusion lymphoma (PEL), an aggressive non-Hodgkin lymphoma caused by Kaposi sarcoma-associated herpesvirus (KSHV), lacks standard therapy and has a median survival of 10–22 months with combination chemotherapy. PEL is a tumor of plasmablast-like B cells generally expressing CD38, the target...

Descripción completa

Detalles Bibliográficos
Autores principales: Shrestha, Prabha, Astter, Yana, Davis, David A., Zhou, Ting, Yuan, Constance M., Ramaswami, Ramya, Wang, Hao-Wei, Lurain, Kathryn, Yarchoan, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828731/
https://www.ncbi.nlm.nih.gov/pubmed/36632565
http://dx.doi.org/10.1080/2162402X.2022.2163784

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9828731/
https://www.ncbi.nlm.nih.gov/pubmed/36632565
http://dx.doi.org/10.1080/2162402X.2022.2163784

Ejemplares similares